Fimbrion Therapeutics (USA) announced that under its joint research collaboration with GSK, researchers have identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs).
Fimbrion and GSK began their joint research efforts in July of 2016. The newly identified clinical candidate is a mannose-containing small molecule that targets an adhesive protein in bacteria called FimH. This novel drug candidate represents a new strategy for treating bacterial infections by preventing the bacteria that cause UTIs from sticking to the walls of the bladder, thus allowing the body to naturally eliminate the infection. Since this mannose-containing compound does not kill bacteria, it potentially could treat and prevent UTIs without inducing antibiotic resistance.
Fimbrion Therapeutics (St. Louis, USA) discovers, develops, and commercializes antimicrobial-sparing, first-in-class anti-virulence drugs for the prevention and treatment of infectious diseases caused by bacteria, including drug-resistant strains. The company has an active pipeline of antimicrobial strategies to combat bacterial infections.